Related Experiment Video

Updated: Feb 27, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.6K

Development of respiratory syncytial virus (RSV) vaccines for infants

Hannah E Gerretsen1, Charles J Sande2

  • 1Oxford Vaccine Group, Department of Paediatrics, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford OX3 7LE, UK.

The Journal of Infection
|June 26, 2017
PubMed

Insights

Developing a respiratory syncytial virus (RSV) vaccine for infants remains challenging due to safety concerns and early disease onset. Recent advances in antigen design and delivery platforms offer new hope for effective infant RSV vaccines.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Immunology

Background:

  • Respiratory Syncytial Virus (RSV) remains a leading cause of infant respiratory illness globally.
  • Despite decades of research, an effective vaccine for pediatric RSV disease has not been achieved.
  • Severe RSV disease incidence peaks in the first three months of life, complicating early intervention strategies.

Observation:

  • Historical vaccine trials faced significant safety hurdles, including enhanced disease severity upon natural infection.
  • The stringent safety criteria for modern vaccines further complicate the development of pediatric RSV vaccines.
  • Reviewing past vaccine failures provides critical insights into current development challenges.

Findings:

  • Analysis of historical RSV vaccine development reveals key reasons for past failures.
  • Recent breakthroughs in vaccine antigen design show promise for improved immunogenicity.
  • Evolving delivery platforms are being explored for effective immunization of seronegative infants.

Implications:

  • Understanding past failures is crucial for navigating current RSV vaccine development.
  • Novel antigen designs and delivery systems may overcome historical safety and efficacy barriers.
  • Successful development of an infant RSV vaccine could significantly reduce childhood morbidity and mortality.

Keywords:
Live attenuated vaccinesRespiratory syncytial virusVaccinesVirus fusion proteinVirus vectored vaccines

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.4K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.4K

Related Concept Videos

Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
1.7K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.3K
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
798
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.3K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
1.2K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
552